Literature DB >> 22665732

International network on endocrine complications in thalassaemia (I-CET): an opportunity to grow.

V De Sanctis1, A T Soliman, M Angastiniotis, A Eleftheriou, Ch Kattamis, M Karimi, M El Kholy, H Elsedfy, Mohd Abdel Daem Mohd Yassin, A El Awwa, I Stoeva, N Skordis, G Raiola, B Fiscina.   

Abstract

Most of the endocrine complications in thalassaemia are attributable to iron overload which may be the result of economic circumstances (expense of the chelation therapy), late onset of chelation therapy or poor compliance with the iron chelation therapy. The major difficulties reported by hematologists or pediatric endocrinologists experienced in thalassaemias or thalassaemia syndromes in following growth disorders and endocrine complications were: lack of familiarity with medical treatment of endocrine complications (40%), interpretation of endocrine tests (30%), costs (65%), absence of paediatric endocrinologist for consultation on growth disorders and endocrine complications (27%), facilities (27%), other (e.g. lack of collaboration and on-time consultation between thalassaemic Centers supervised by hematologists and endocrinologists) (17%). Because any progress we make in research into growth disorders and endocrine complications in thalassaemia should be passed on to all those suffering from it, guaranteeing them the same therapeutic benefits and the same quality of life, on the 8th of May, 2009 in Ferrara (Italy), the International Network on Endocrine Complications in Thalassemia (I-CET) was founded. The I-CET group is planning to conduct, in Ferrara in May 2012, a workshop, "MRI and Endocrine Complications in Thalassaemia", and in Doha (Qatar) in September 2012, a 3-day intensive course entitled, "Growth disorders and Endocrine Complications in Thalassaemia", to provide interested pediatricians, physicians and hematologists from all over the world with an in-depth approach to the diagnosis and management of growth and endocrine disorders in thalassaemic patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665732

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  3 in total

1.  Does Insulin Like Growth Factor-1 (IGF-1) Deficiency Have a "Protective" Role in the Development of Diabetic Retinopathy in Thalassamia Major Patients?

Authors:  Vincenzo De Sanctis; Carlo Incorvaia; Ashraf T Soliman; Giancarlo Candini; Alessia Pepe; Christos Kattamis; Nada A Soliman; Heba Elsedfy; Mohamed El Kholy
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-05-20       Impact factor: 2.576

Review 2.  Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis.

Authors:  Li-Na He; Wei Chen; Yi Yang; Ying-Jun Xie; Ze-Yu Xiong; Di-Yu Chen; Dian Lu; Neng-Qing Liu; Ying-Hong Yang; Xiao-Fang Sun
Journal:  Biomed Res Int       Date:  2019-04-18       Impact factor: 3.411

3.  Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Heba Elsedfy; Nicos Skordis; Christos Kattamis; Michael Angastiniotis; Mehran Karimi; Mohd Abdel Daem Mohd Yassin; Ahmed El Awwa; Iva Stoeva; Giuseppe Raiola; Maria Concetta Galati; Elsaid M Bedair; Bernadette Fiscina; Mohamed El Kholy
Journal:  Indian J Endocrinol Metab       Date:  2013-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.